Correction: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells

Chun-Hao Tsai; Hsiao-Chi Tsai; Ho-Ning Huang; Chih-Hung Hung; Chin-Jung Hsu; Yi-Chin Fong; Horng-Chaung Hsu; Yuan-Li Huang; Chih-Hsin Tang

doi:10.18632/oncotarget.26303

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells

PDF | How to cite

Oncotarget. 2018; 9:35598-35598. https://doi.org/10.18632/oncotarget.26303

Metrics: PDF 1433 views | ?

Chun-Hao Tsai^1,2,*, Hsiao-Chi Tsai^3,*, Ho-Ning Huang⁴, Chih-Hung Hung², Chin- Jung Hsu^2,5, Yi-Chin Fong^2,5, Horng-Chaung Hsu^1,2, Yuan-Li Huang⁴ and Chih-Hsin Tang^3,4,6

¹ Department of Medicine and Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
² Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan
³ Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan
⁴ Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan
⁵ School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
⁶ Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan
^* These authors have contributed equally to this work

Published: October 30, 2018

This article has been corrected: Due to an accidental duplication, the images for Grade I MMP-2 staining and Normal Cartilage Resistin staining in Figure 5A are identical. The corrected Figure 5A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:258-270. DOI: https://doi.org/10.18632/oncotarget.2724.

Figure 5: Clinical importance of resistin, matrix metalloproteinase (MMP-2), and microRNA (miR)-519d in chondrosarcoma. (A-C) Immunohistochemical staining of resistin and MMP-2 in normal cartilage and chondrosarcoma tissue. Correlations between (D) resistin/MMP-2, (E) resistin/miR-519d, and (F) MMP-2/mi-519d in human chondrosarcoma tissues.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26303

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells